A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer (NCT01791829)
🩺 Plain-English Summary (8th-Grade Level)
This is a multicentre, single-arm prospective cohort study evaluating risk of ipsilateral breast tumour recurrence(IBTR) following breast conserving surgery (BCS) in a group of women postulated to be at low risk for recurrence. Women with luminal A breast cancer determined by immunohistochemical(IHC) and other low risk clinical testing (see below) will be treated with endocrine therapy (tamoxifen or aromatase inhibitor) for five years and will not be treated with breast irradiation (BI). Subjects will be followed for 10 years and will be assessed for recurrent disease, new primary cancer and survival.
Who can join: Review the eligibility criteria below.
Location: Tom Baker Cancer Centre — Calgary, Alberta
Age range: 55 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Tom Baker Cancer Centre — Calgary, Alberta
- Abbotsford Centre — Abbotsford British Columbia, British Columbia
- BC Cancer Agency, Centre for the North — Prince George, British Columbia
- BCCA - Vancouver Centre — Vancouver, British Columbia
- BC Cancer Agency — Victoria, British Columbia
- Cancer Care Manitoba — Winnipeg, Manitoba
- Royal Victoria Regional Health Centre — Barrie, Ontario
- Northeastern Ontario Regional Cancer Centre — Greater Sudbury, Ontario
- Juravinski Cancer Centre — Hamilton, Ontario
- Cancer Centre of Southern Ontario at Kingston — Kingston, Ontario
- Grand River Regional Cancer Centre — Kitchener, Ontario
- London Regional Cancer Centre — London, Ontario
- R.S. McLaughlin Durham Regional Cancer Centre — Oshawa, Ontario
- Ottawa Regional Cancer Centre — Ottawa, Ontario
- Algoma District Cancer Program — Sault Ste. Marie, Ontario
- Niagara Health System — St. Catharines, Ontario
- Thunder Bay Regional Health Sciences — Thunder Bay, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- Centre integre de sante et de services sociaux de laval (CISSS de Laval) — Laval, Quebec
- CHUM - Hopital Notre Dame — Montreal, Quebec
- The Jewish General Hospital — Montreal, Quebec
- McGill University Health Centre — Montreal, Quebec
- CHUQ - Pavillon Hotel-Dieu de Quebec — Québec, Quebec
- CHUS - Hopital Fleurimont — Sherbrooke, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.